Welcome to the RWT Staff Publications Repository
The repository contains the records of published and unpublished research authored by NHS staff working for the Royal Wolverhampton NHS Trust and its partners. The repository is managed by the Library and Knowledge Services of the Trust and supported by the Non-Medical Research Leads Network Group and the Research and Development Directorate.
If you are a member of RWT staff and you would like to submit an item to the repository, please fill in this online form.
If you have a list of publications you'd like to submit, please e-mail the repository email@example.com admin team.
Communities in RWT Staff Repository
Select a community to browse its collections.
(Journal of Thoracic Oncology, Elsevier., 2014-10-01)The importance of submitting data of clinical response to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in patients with uncommon EGFR mutations has been encouraged.1 In view of this, we present ...
Is hormone replacement therapy in post-menopausal women associated with a reduced risk of oesophageal cancer? (United European Gastroenterology Journal, Wiley Online, 2014-10-01)Purpose The rise in oesophageal adenocarcinoma incidence in women with age is delayed compared with men until the post-menopausal period. A matched cohort study was therefore undertaken of post-menopausal women on hormone ...
Reduced testing frequency for glycated hemoglobin, HbA1c, is associated with deteriorating diabetes control. (Diabetes Care, American Diabetes Association., 2014-10-01)OBJECTIVE We previously showed that in patients with diabetes mellitus, glycated hemoglobin (HbA1c) monitoring outside international guidance on testing frequency is widespread. Here we examined the relationship between ...
(British Journal of Nursing, Mark Allen Publishing., 2014-10-01)It is important to maintain healthy blood lipid profiles in order to reduce risk of cardiovascular disease. This article explores some of the evidence for natural cholesterol lowering products as a possible alternative to ...
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial (The Lancet, Elsevier., 2014-10-01)Background VEGFR-2 has a role in gastric cancer pathogenesis and progression. We assessed whether ramucirumab, a monoclonal antibody VEGFR-2 antagonist, in combination with paclitaxel would increase overall survival in ...